MS Views and News Be empowered with MS views and news. To receive The MS BEACON e-Newsletter, CLICK HERE - -

Visit our MS learning channel on YouTube, which provides hundreds of MS educational videos presented by MS Experts from across the USA. Archived here: -- Also please visit our Social media platforms: Facebook, Twitter, and Instagram . Each providing important information for the MS community. Furthermore, scroll down the left side of this blog to learn from the resources and links.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, for your personal knowledge and to keep you informed of current health-related issues. It is not a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.


Friday, September 11, 2009

More favourable results on another Oral MS therapy in testing

LONDON, Sept 11 (Reuters) - Patients given an experimental multiple sclerosis tablet from Sanofi-Aventis (SASY.PA) showed a significant improvement compared to those on placebo in a mid-stage test, researchers said on Friday.

Teriflunomide, which was used as an add-on therapy to interferon beta in the Phase II clinical trial, is one of a number of MS drugs in development that are designed to be given by mouth rather than injection or infusion.

In the 24-week study, patients on the new drug experienced a 56 percent and 81 percent reduction in cerebral inflammatory lesions compared to those on placebo, as measured by MRI scan, on two different doses of the drug, which was well tolerated.

"These results encourage longer-term studies to establish the clinical benefit of combination treatment in this disease where effective new therapies are eagerly awaited," investigator Mark Freedman of the University of Ottawa said in a statement.

Teriflunomide is currently being evaluated in final-stage Phase III studies.


No comments: